These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27172118)

  • 1. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2016 Oct; 19(10):995-1002. PubMed ID: 27172118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
    Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes.
    Orme ME; Jurewicz WA; Kumar N; McKechnie TL
    Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.
    McEwan P; Dixon S; Baboolal K; Conway P; Currie CJ
    Pharmacoeconomics; 2006; 24(1):67-79. PubMed ID: 16445304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice.
    Muduma G; Odeyemi I; Pollock RF
    Drugs Real World Outcomes; 2016 Mar; 3(1):61-68. PubMed ID: 27747802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; You RX; Guo M; Zeng L; Zhou P; Zhu L; Xu G; Li J; Liu D
    Am J Ther; 2016; 23(3):e810-24. PubMed ID: 25299636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of everolimus plus reduced tacrolimus in de novo liver-recipients in the Italian setting.
    Bianic F; Campbell R; Damera V; De Simone P; Roccia A; Gregson J; Ricci JF
    J Med Econ; 2016 Sep; 19(9):866-73. PubMed ID: 27081739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
    Snowsill TM; Moore J; Mujica Mota RE; Peters JL; Jones-Hughes TL; Huxley NJ; Coelho HF; Haasova M; Cooper C; Lowe JA; Varley-Campbell JL; Crathorne L; Allwood MJ; Anderson R
    Nephrol Dial Transplant; 2017 Jul; 32(7):1251-1259. PubMed ID: 28873970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.
    Lazzaro C; McKechnie T; McKenna M
    J Nephrol; 2002; 15(5):580-8. PubMed ID: 12455727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom.
    McEwan P; Baboolal K; Conway P; Currie CJ
    Clin Ther; 2005 Nov; 27(11):1834-46. PubMed ID: 16368455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients.
    Altieri M; Delaval G; Kimmoun E; Allaire M; Salamé E; Dumortier J
    Exp Clin Transplant; 2018 Jun; 16(3):321-325. PubMed ID: 28697715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant.
    Muduma G; Saunders R; Odeyemi I; Pollock RF
    PLoS One; 2016; 11(11):e0160421. PubMed ID: 27812112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation.
    Liu JY; Song M; Guo M; Huang F; Ma BJ; Zhu L; Xu G; Li J; You RX
    Am J Ther; 2016; 23(6):e1720-e1728. PubMed ID: 25569597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients.
    Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC
    J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
    Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
    Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.